Gelteq Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Net Revenue (AUD) Annually413KTarget: Significant growth driven by commercialization and partnerships
Net Loss (AUD) Annually-6.6MTarget: Reduction in losses through commercial scale-up
Cash and Cash Equivalents (AUD) Quarterly9.3KTarget: Strengthened by strategic debt financing of up to USD 3.5 million
Watch Items
- FDA Regulatory Pathway for Veterinary Antiparasitic Drug CandidateTrigger: FDA application submission targeted for later in 2026Action: Monitor clinical trial data updates expected in July 2026
- First Human Clinical Trial CommencementTrigger: Trial initiation expected in Q3 2026 (beginning July 1, 2026)Action: Track patient enrollment and initial safety/efficacy readouts
- Strategic Debt Financing DrawdownsTrigger: Shareholder vote on June 18, 2026 for the remaining USD 2.5 million trancheAction: Verify approval and subsequent funding of the second tranche
Research as of 20 Jun 2026